Edition:
United States

H Lundbeck A/S (HLUKF.PK)

HLUKF.PK on OTC Markets Group

42.30USD
--
Change (% chg)

-- (--)
Prev Close
$42.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
604
52-wk High
$42.65
52-wk Low
$31.35

Select another date:

Mon, Nov 7 2016

BRIEF-Lundbeck: board member buys 15,000 shares at DKK 242.01

* Board member Lars Holmqvist purchased on Nov. 7 total of 15,000 Lundbeck shares at 242.01 Danish crowns ($36)

UPDATE 2-Lundbeck highlights turnaround with upgraded profit forecast

* Shares up 8 pct (Adds detail, CEO quotes, updates share price)

Lundbeck raises its 2016 revenue and profit forecasts

COPENHAGEN, Nov 2 Danish pharmaceutical group lifted its full-year revenue and operating profit forecasts after posting a better than expected quarterly result.

BRIEF-Lundbeck: FDA approves Carnexiv injection

* U.S. FDA approves Carnexiv (Carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations

BRIEF-Ligand says partner Lundbeck plans to make Carnexiv commercially available in U.S. in early 2017

* Partner Lundbeck receives FDA approval of Carnexiv(tm) (carbamazepine) injection as intravenous short-term replacement therapy for certain seizure types

European shares pull back after Fed-inspired rally; Lundbeck slumps

MILAN, Sept 23 European shares fell in early trading on Friday, pulling back from two-week highs hit in the previous session following the U.S. Federal Reserve's decision to push back on its next rate increase.

Lundbeck says Alzheimer's drug fails in late-stage study

Danish drugmaker H Lundbeck A/S's highly anticipated experimental Alzheimer's drug failed in a late-stage study, underscoring the challenges faced by drugmakers to tackle the debilitating memory-robbing disease.

UPDATE 2-Lundbeck says Alzheimer's drug fails in late-stage study

Sept 22 Danish drugmaker H Lundbeck A/S's highly anticipated experimental Alzheimer's drug failed in a late-stage study, underscoring the challenges faced by drugmakers to tackle the debilitating memory-robbing disease.

BRIEF-Lundbeck says alzheimer's drug late stage study fails

* Conclusions from first out of three phase 3 studies on idalopirdine in alzheimer's disease

BRIEF-Lundbeck CFO sells 51,000 shares

* EVP and CFO, Anders Götzsche, sold on Sept. 9 total of 39,939 Lundbeck shares at price of 262.04 Danish crowns ($39.55) and on Sept. 12 total of 11,061 Lundbeck shares at price of 257.02 crowns Source text for Eikon: Further company coverage: ($1 = 6.6261 Danish crowns) (Gdynia Newsroom)

Select another date: